A 26-year-old pregnant patient asks about smoking cessation. Which option is most suitable to offer initially?

A 26-year-old pregnant patient asks about smoking cessation. Which option is most suitable to offer initially?

• A. Nicotine gum
• B. Varenicline
• C. Bupropion
• D. Electronic cigarettes

Answer: (B)

Varenicline is the best initial pharmacotherapy here because it directly targets the nicotine receptors to both ease withdrawal and reduce the rewarding effects of smoking. It acts as a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, which lowers craving and helps sustain abstinence more effectively than other listed options. Nicotine gum provides nicotine replacement and can help with withdrawal, but its quit-rate advantage is generally smaller than that of varenicline. Electronic cigarettes raise concerns about fetal exposure to nicotine and other substances, making them less suitable as a first-line choice. Bupropion has useful effects for some patients but typically shows lower cessation success rates compared with varenicline in head-to-head comparisons. In pregnancy, data are limited for all pharmacotherapies, so safety considerations are important, but when focusing on efficacy among the available choices, varenicline offers the strongest potential to aid quitting.

Varenicline is the best initial pharmacotherapy here because it directly targets the nicotine receptors to both ease withdrawal and reduce the rewarding effects of smoking. It acts as a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, which lowers craving and helps sustain abstinence more effectively than other listed options. Nicotine gum provides nicotine replacement and can help with withdrawal, but its quit-rate advantage is generally smaller than that of varenicline. Electronic cigarettes raise concerns about fetal exposure to nicotine and other substances, making them less suitable as a first-line choice. Bupropion has useful effects for some patients but typically shows lower cessation success rates compared with varenicline in head-to-head comparisons. In pregnancy, data are limited for all pharmacotherapies, so safety considerations are important, but when focusing on efficacy among the available choices, varenicline offers the strongest potential to aid quitting.